HyperMed Imaging, Inc. Hires New CEO
January 1, 2012 / Greenwich, CT
HyperMed Imaging, Inc. has hired Mark Darty as its new CEO. Mr. Darty is a seasoned medical device executive that brings a wealth of experience in value creation and commercialization of new and market disruptive technologies. He has held board and operations management positions in cutting edge companies ranging from startups to large, established industry leaders. During his 28-year career, he has brought emerging technologies from the drawing board to production and revenue bearing status in the medical device, consumer electronics, automotive and aerospace sectors.
Prior to joining HyperMed, Mr. Darty was Executive VP of Operations for Luminetx, an award winning medical device company specializing in vascular imaging. From 2005 through 2010, he led the company’s technical operations from inception through global commercialization. The company was listed among Red Herring’s Top 100 startups and won several awards including the Medical Design Excellence Award. When acquired, the company had sales in over 20 nations with manufacturing operations in the US and Europe. Prior to 2005, Mr. Darty held senior management and technical positions at companies such as Brother International and McDonnell Douglas (Boeing), where he led the development, commercialization and manufacturing of new technologies and products such as avionics, mobile computing equipment, imaging devices, and nanotechnology materials and devices. Mr. Darty earned a Master’s of Science in Engineering from the University of Alabama and a Bachelor’s of Science in Electrical Engineering from the University of Tennessee. He is an inventor with many patents ranging from medical devices to electronics, software and nanotechnology.
HyperMed Imaging, Inc. is a privately owned medical device company and the market leader in hyperspectral medical imaging. HyperMed pioneered the use of its novel version of hyperspectral imaging for assessment of surface tissue oximetry with its OxyVu™-1 device, first cleared by the FDA in 2006. HyperMed’s OxyVu-1 has generated substantial clinical research for the use of the technology in a number of applications involving circulatory compromise. HyperMed is now engaged in the research and development of a new generation of devices using its proprietary hyperspectral imaging technology.
